title: Bevacizumab for choroidal neovascularization related to inflammatory diseases.
abstract: OBJECTIVE
  The purpose of this study was to report our experience with intravitreal bevacizumab for inflammation-related choroidal neovascularization in two tertiary centers.
  
  
  METHODS
  This study was a retrospective analysis of patients with choroidal neovascularization related to inflammatory diseases, treated with intravitreal bevacizumab injections (1.25 mg/0.05 mL).
  
  
  RESULTS
  Ten eyes of 10 patients (range, 14-78 years; mean age, 44 years) with underlying uveitis were treated with intravitreal bevacizumab for inflammation-related choroidal neovascularization from 2006 to 2008. Mean follow-up time was 13 +/- 8 months, and the mean number of injections was 2.7 +/- 2. Resolved leakage on fluorescein angiography and resolution of subretinal fluid on optical coherence tomography occurred in all patients, with improvement in visual acuity in 9 of 10 eyes and no change in visual acuity in 1 of 10 eyes. Seven patients received additional treatment based on the underlying condition. Mean macular thickness on optical coherence tomography decreased from 394 +/- 116 microm to 254 +/- 52 microm (P < 0.01). Mean visual acuity improved from 0.87 +/- 0.74 logarithm of the minimum angle of resolution to 0.38 +/- 0.63 (P = 0.005). Seven patients reached a visual acuity of 0.2 logarithm of the minimum angle of resolution (Snellen 6/9) or better.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab is an effective treatment for choroidal neovascularization related to inflammatory diseases when inflammation is controlled.
authors.affiliation: Department of Ophthalmology, Rabin Medical Center, Petach Tikva, Israel. mkramer@netvision.net.il
authors.forename: Michal
authors.initials: M
authors.lastname: Kramer
authors.forename: Ruth
authors.initials: R
authors.lastname: Axer-Siegel
authors.forename: Tareq
authors.initials: T
authors.lastname: Jaouni
authors.forename: Ehud
authors.initials: E
authors.lastname: Reich
authors.forename: Itzhak
authors.initials: I
authors.lastname: Hemo
authors.forename: Ethan
authors.initials: E
authors.lastname: Priel
authors.forename: Edward
authors.initials: E
authors.lastname: Averbukh
authors.forename: Rita
authors.initials: R
authors.lastname: Ehrlich
authors.forename: Itay
authors.initials: I
authors.lastname: Chowers
authors.forename: Dov
authors.initials: D
authors.lastname: Weinberger
authors.forename: Radgonde
authors.initials: R
authors.lastname: Amer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007267:Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab